Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D.
D'Haens G, et al. Among authors: zou g.
Lancet Gastroenterol Hepatol. 2024 Nov 18:S2468-1253(24)00317-0. doi: 10.1016/S2468-1253(24)00317-0. Online ahead of print.
Lancet Gastroenterol Hepatol. 2024.
PMID: 39571587